Verastem
Verastem Oncology (Verastem, Inc.) is a development-stage biopharmaceutical company focused on developing novel therapies for cancers driven by the RAS/MAPK pathway, including KRAS-mutant tumors. Its work includes the first FDA-approved treatment for KRAS-mutant recurrent low-grade serous ovarian cancer, plus a pipeline targeting KRAS G12D inhibition. As a clinical-stage pharmaceutical company it publishes no public developer API, developer portal, or SDKs; this profile was surfaced as a portfolio company of bessemer-venture-partners and enriched with verified identity only.
Verastem is profiled on the APIs.io network. Tagged areas include Company, Healthcare, Biotechnology, Pharmaceuticals, and Oncology.
Kin Score
Markets this provider is in provisional
The Kin Score Market layer reads a provider inside its market: its position, and how deep its integrations go. Depth is only comparable within a position. Provisional and unweighted: not part of the Kin Score or agent readiness.
| Market | Position | Depth | Registered MCP server | Declares compatibility |
|---|---|---|---|---|
| Clinical Trial Sponsors (drug pipelines) | standard | 56.0 | - | - |
Registered MCP server and declares compatibility are report only — not weighted. Undeclared means we found nothing we can read, so there is no number: we never infer integrations.
Resources
Company 2
The organization behind the API
Other 1
Properties that don't map to a standard resource type
Source (apis.yml)
Work with this as data
Every provider here is available over the APIs.io API and to AI agents over MCP.